<DOC>
	<DOCNO>NCT00776191</DOCNO>
	<brief_summary>The purpose study demonstrate increase protein metabolism treatment Physioneal 35® ( contain lactate 10 mmol/l , calcium 1.75 mmol/l ) compare treatment Physioneal 40® ( contain lactate 15 mmol/l , calcium 1.25 mmol/l ) child adolescent end stage renal failure receive peritoneal dialysis .</brief_summary>
	<brief_title>Randomized Multicenter Cross-over Study Compare Effect Physioneal 35 40 Protein Metabolism</brief_title>
	<detailed_description>- Fat oxidation ( 13C-enrichment expiration breath sample U-C13-algae turnover ) - Growth marker ( plasma level IgF-1 , IgF-BP3 , leptin ) - Biochemical marker anabolism ( plasma level total protein , albumin , transferrin ) - Serum thyroid function ( fT3 , fT4 , TSH ) - Serum lipid status - Serum marker calcium/phosphate metabolism ( PTH , calcium , ionized calcium , phosphate , alkaline phosphatase ) - Prevalence metabolic acidosis/ alkalosis ( venous sample ) , serum lactate - Safety parameter ( normalized weekly Kt/v , parameter glucose metabolism , parameter hepatic function , parameter calcium-phosphate-metabolism , physical examination incl . stand height , weight , assessment complication relate peritoneal dialysis peritonitis , exit infection inguinal hernia ) - Body composition ( lean body mass body fat mass/fluid )</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients male nonpregnant female age 3 month 18 year . Patients regular automate peritoneal dialysis due end stage renal failure least 3 month . Patients and/or parent must capable understand purpose risk study . Patients and/or parent ( guardian ) willing give write informed consent willing participate comply study protocol . Use pure lactate , amino acid oligosaccharide solution peritoneal dialysis Peritonitis episode le 6 week enrolment Hypercalcemia ( serum ) &gt; 2.75 mmol/l three independent measurement 10 day Severe secondary hyperthyroidism ( iPTH &gt; 500 ng/l ) Renal anemia hemoglobin ( blood ) &lt; 10 mg/dl Impaired hepatic function ( AST/SGOT ALT/SGPT &gt; 2 time upper limit reference range ) Patients participate another study require Ethics Committee approval . Noninterventional study permit . Pregnant female patient , female childbearing potential unwilling unable use adequate contraception method . Severe respiratory insufficiency Malnourishment ( body weight &lt; 2.5 SDS height gender ) severe deterioration fat metabolism Patients history malignancy organ system , treat untreated Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion investigational product comparator , include Major deterioration abdominal wall ( e.g . dermal infection burn , hernia ) Major deterioration abdominal cavity ( e.g . ascites , ileus , adhesion , bowel perforation , defect diaphragm , tumour ) Patients history viral infection HIV hepatitis B , C .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Physioneal 35</keyword>
	<keyword>Physioneal 40</keyword>
	<keyword>child</keyword>
	<keyword>chronic peritoneal dialysis</keyword>
</DOC>